comparemela.com

Latest Breaking News On - Yazeedy sawalha - Page 1 : comparemela.com

Chemo-Free Quadruplet Promising as Initial Treatment in DLBCL

Approach could allow for a response-adapted reduction of CHOP

United statesKamij maddocksGreg laubYazeedy sawalhaAmerican society of hematologyOhio state university wexner medical centerSmart stopAmerican societyMedpage todaySmart startSenior director

Tisa-Cel Yields Durable Responses in R/R Follicular Lymphoma

Our panel of experts discuss 3-year findings from the phase II ELARA study

United statesGreg laubKamij maddocksYazeedy sawalhaAmerican society of hematologyOhio state university wexner medical centerAmerican societyMedpage todayRelapse refractory follicular lymphoma treatedYear follow upSenior director

Positive Results for Odronextamab in Relapsed/Refractory DLBCL

But experts aren't sure where it would fit in with currently approved bispecifics

United statesKami maddocksKamij maddocksYazeed sawalhaYazeedy sawalhaOhio state university wexner medical centerOhio state university james comprehensive cancer centerOhio state universityAmerican society of hematologyAmerican societyMedpage todayIm yazeed sawalhaOhio stateKim david

Responses to Mosunetuzumab in Follicular Lymphoma Remain Durable at 3 Years

Bispecific antibody also shows high response rates in frontline setting

United statesOhio state universityMosunetuzumab lunsumioKamij maddocksYazeedy sawalhaGreg laubKami maddocksYazeed sawalhaOhio state university wexner medical centerAmerican society of hematologyOhio state university james comprehensive cancer centerAmerican societyMedpage todayIm yazeed sawalhaIm david bondOhio state

vimarsana © 2020. All Rights Reserved.